Active substanceAcyclovirAcyclovir
Similar drugsTo uncover
  • Acigerpine
    cream externally 
  • Acyclovir
    pills inwards 
    AVVA RUS, OJSC     Russia
  • Acyclovir
    cream externally 
    ATOLL, LLC     Russia
  • Acyclovir
    lyophilizate in / in 
    ALVILS, LTD.     Russia
  • Acyclovir
    pills inwards 
  • Acyclovir
    cream locally externally 
    VERTEKS, AO     Russia
  • Acyclovir
    pills inwards 
  • Acyclovir
    ointment locally externally 
    OZONE, LLC     Russia
  • Acyclovir
    pills inwards 
    AVEKSIMA, JSC     Russia
  • Acyclovir
    ointment externally 
  • Acyclovir
    lyophilizate in / in d / infusion 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Acyclovir
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Acyclovir
    ointment externally 
  • Acyclovir
    ointment d / eye 
    SYNTHESIS, OJSC     Russia
  • Acyclovir
    ointment externally 
    VERTEKS, AO     Russia
  • Acyclovir
    pills inwards 
  • Acyclovir
    ointment externally 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Acyclovir
    ointment locally externally 
    ALVILS, LTD.     Russia
  • Acyclovir
    ointment locally externally 
    AZT PHARMA KB, LLC     Russia
  • Acyclovir
    ointment externally 
    NIZHFARM, JSC     Russia
  • Acyclovir
    ointment externally 
    ALTAYVITAMINS, CJSC     Russia
  • Acyclovir
    pills inwards 
    NIZHFARM, JSC     Russia
  • Acyclovir
    pills inwards 
    OZONE, LLC     Russia
  • Acyclovir
    ointment externally 
  • Acyclovir
    pills inwards 
    OZONE, LLC     Russia
  • Acyclovir
    pills inwards 
    SYNTHESIS, OJSC     Russia
  • Acyclovir
    ointment externally 
    GREEN DUBRAVA, CJSC     Russia
  • Acyclovir
    pills inwards 
  • Acyclovir Belupo
    cream externally 
  • Acyclovir Belupo
    pills inwards 
  • Acyclovir Sandoz®
    pills inwards 
    Sandoz d.     Slovenia
  • Acyclovir Sandoz®
    cream externally 
    Sandoz d.     Slovenia
  • Acyclovir forte
    pills inwards 
  • Acyclovir-AKOS
    pills inwards 
    SYNTHESIS, OJSC     Russia
  • Acyclovir-Abrichin
    ointment externally 
    AKRIKHIN HFK, JSC     Russia
  • Acyclovir-Ferein
    cream externally 
    BRYNTSALOV-A, CJSC     Russia
  • Acyclostad®
    pills inwards 
  • Vivorax
    cream externally 
  • Vivorax
    pills inwards 
  • Virollex
    cream externally 
  • Virollex
    lyophilizate d / infusion 
  • Gervirax
    cream externally 
  • Gerperax
    ointment externally 
  • Gerperax
    pills inwards 
  • Zovirax ®
    lyophilizate d / infusion 
  • Zovirax ®
    ointment d / eye 
  • Zovirax ®
    pills inwards 
  • Zovirax ®
    cream externally 
  • Medovir
    powder d / infusion 
    Medocemi Co., Ltd.     Cyprus
  • Provirsan®
    pills inwards 
    PRO.MED.CS Prague as.     Czech Republic
  • Dosage form: & nbsplyophilizate for solution for infusion
    Composition:1 bottle contains:

    Active substance:

    Acyclovir in the form of a sodium salt 274.40 mg (corresponding to 250 mg of acyclovir).

    Description:

    Liofilizate in the form of a porous mass of white or almost white color.

    Pharmacotherapeutic group:Antiviral agent
    ATX: & nbsp

    S.01.A.D   Antiviral drugs

    Pharmacodynamics:

    Acyclovir is a synthetic analogue of a purine nucleoside, which has activity against herpes viruses, including Herpes simplex (type I and II), Varicella zoster, Epstein Barr virus, Cytomegalovirus.

    Acyclovir has a high selectivity of action. Thymidine kinase virus-infected cells consistently converts acyclovir in monophosphate, diphosphate and triphosphate of acyclovir. Acyclovir triphosphate inhibits viral DNA polymerase and competitively replaces deoxyguanosine triphosphate in DNA viruses. Thus, defective viral DNA is formed, which depresses the replication of new viruses.

    Acyclovir is effective against the virus Herpes simplex 1 and 2 types, the virus causing varicella and shingles (Varicella zoster), of the Epstein-Barr virus (the types of viruses are listed in ascending order of the MPC of acyclovir). Acyclovir moderately effective against cytomegalovirus (CMV). With herpes, prevents the formation of new elements of the rash, reduces the likelihood of cutaneous dissemination and visceral complications, accelerates the formation of crusts, reduces pain in the acute phase of herpes zoster. It has an immunostimulating effect.

    Pharmacokinetics:

    With an intravenous drip for 1 hour at a dose of 2.5 mg / kg, 5 mg / kg and 10 mg / kg, the maximum concentration is 5.1, 9.8 and 20.7 μg / ml, respectively.The maximum concentration is observed after 7 hours - 0.5, 0.7 and 2.3 μg / ml, respectively. When the drug is prescribed children over 1 year old in a dose of 250 and 500 mg / square meter. the maximum and minimum concentrations are the same as in adults with a dose of 5 and 10 mg / kg.

    In newborns and children under 3 months. when acyclovir is administered at a dose of 10 mg / kg, intravenously drip for 1 hour 3 times a day, the maximum concentration is 13.8 μg / ml and the minimum concentration is 2.3 μg / ml.

    Acyclovir penetrates the blood-brain barrier (GEB) and the placental barrier, excreted in breast milk. Acyclovir it penetrates well into organs and tissues (including the brain, kidneys, lungs, liver, lacrimal fluid, intestines, muscles, spleen, uterus, secret of the vagina, sperm, amniotic fluid, contents of herpetic vesicles).

    Binding to plasma proteins is from 9-33%.

    Metabolised in the liver to form a metabolite of 9-carboxymethoxymethylguanine (8.5-14% acyclovir). It is mainly excreted by the kidneys by glomerular filtration and tubular secretion: when administered intravenously, it is 80% unchanged, and in a smaller amount (less than 2%) is excreted through the intestine.

    The half-life after intravenous administration in adults is 2.9 hours, in children up to 3 months. - 3.8 hours (with drip intravenous 10 mg / kg for 1 hour 3 times a day), in children and adolescents from 1 to 18 years - 2.6 hours.

    In patients with severe chronic renal insufficiency, the half-life is 20 hours, with hemodialysis - 5.7 hours (the concentration of acyclovir in the plasma decreases to 60% of the initial value).

    In renal failure, the half-life (depending on the value of creatinine clearance) is: for creatinine clearance (CC) 80 ml / min - 2.5 hours, 50-80 ml / min - 3 hours, 15-50 ml / min - 3 , 5 hours, with anuria - 19.5 hours, during hemodialysis - 5.7 hours, with constant ambulatory peritoneal dialysis - 14-18 hours.

    Indications:
    • Treatment of primary and recurrent severe genital herpes (including patients with impaired immunity).
    • Treatment of primary and recurrent herpes simplex with skin and mucous membrane damage caused by herpes simplex virus, in patients with reduced immunity.
    • Encephalitis caused by the virus Herpes simplex 1 and 2 types.
    • Treatment of herpes zoster caused by the virus Varicella zoster in patients with impaired immunity and without compromising immune status.
    • Treatment of herpes zoster with damage to the eyes, ears, as well as in patients older than 50 years.
    • Generalized infection in the newborn caused by the virus Herpes simplex.
    • Varicella in patients with impaired immunity.
    Contraindications:
    • Hypersensitivity to acyclovir or any other component of the drug;
    • lactation period.
    Carefully:Carefully Acyclovir Introduce patients with renal insufficiency (risk of nephrotoxic action), elderly patients, with dehydration, neurological disorders or neurological reactions to the use of cytotoxic drugs (including in the history), pregnancy.
    Pregnancy and lactation:

    In pregnancy, use is possible in cases where the intended benefit to the mother exceeds the potential risk to the fetus.

    Acyclovir is excreted in breast milk, so the use of the drug during lactation is not recommended.

    Dosing and Administration:

    Intravenously drip for at least 1 hour.

    The contents of the vial are dissolved in aseptic conditions immediately before use.To prepare the solution use water for injection or 0.9% solution of sodium chloride: 10 ml of solution is added to the bottle and intensively

    stir until completely dissolved. The resulting solution is further diluted to a final concentration of acyclovir - no more than 0.5% (5 mg / ml): usually the contents of one vial (250 mg of acyclovir) are diluted in at least 50 ml of saline or, respectively, the contents of two bottles (500 mg acyclovir) in 100 ml of physiological saline. Thus, the resulting solution is used for intravenous slow or drop infusion.

    To administer the solution to children and newborns, where the volume of infusion fluid should be minimized, it is recommended to dissolve the contents of one vial (250 mg of acyclovir) in 10 ml of water for injection or saline. Then add the infusion solution in an amount corresponding to the proportion: 1: 5. For example, in order to obtain a solution containing 100 mg of acyclovir, add 20 ml of the infusion solution to 4 ml of the resulting solution until a final solution with a concentration of 5 mg / ml of acyclovir is obtained.

    As infusion solutions use: isotonic sodium chloride solution (0.9%) or Ringer's lactate solution.

    The prepared solution remains stable for 12 hours at a temperature of 15 to 25 ° C.

    Solutions should not be frozen. If it is found in the solutions prepared for infusion of any opacities or crystallization, they can not be used.

    Adults:

    Acyclovir is injected intravenously at a constant rate for 1 hour.

    With severe genital herpes: initial therapy - adults and children over 12 years - 5 mg / kg every 8 hours for 5-7 days; children under 12 years of age - 250 mg / sq. m. every 8 hours for 5-7 days.

    In the treatment of herpes simplex with lesions of the skin and mucous membranes in patients with a decreased immune status: adults and children over 12 years of age - 5-10 mg / kg every 8 hours for 7 days; children under 12 years of age - 250 mg / m each2 every 8 hours for 7 days.

    Encephalitis caused by the virus Herpes simplex 1 and 2 types: adults and children over 12 years of age - 10 mg / kg every 8 hours, children from 3 months to 12 years - 20 mg / kg every 8 hours (or 500 mg / m2 every 8 hours). The average course of treatment is 20 days.

    With herpes zoster caused by the virus Varicella zoster in patients with impaired immunity: adults and children over 12 years of age - 10 mg / kg every 8 hours for 7-10 days; children under 12 years of age - 20 mg / kg every 8 hours (or 500 mg / m2 every 8 hours) for 7-10 days.

    Generalized infection in newborns, virus-induced Herpes simplex: newborns and children up to 3 months - 10 mg / kg every 8 hours. The average course of treatment is 10 days. It is possible to increase the dose to 15-20 mg / kg every 8 hours, however, the effectiveness and safety of the use of such doses are not established.

    To patients of advanced age

    A dose reduction may be required.

    In case of impaired renal function

    Creatinine clearance

    Dose

    25-50 ml / min

    5-10 mg / kg body weight or 500 mg / m2 every 12 hours

    10-25 ml / min

    5-10 mg / kg body weight or 500 mg / m2 every 24 hours

    0-10 ml / min

    Patients on peritoneal dialysis 2.5-5 mg / kg body weight, or 250 mg / m2 every 24 hours

    Patients on hemodialysis 2.5-5 mg / kg body weight, or 250 mg / m2 every 24 hours and after dialysis.

    Side effects:

    From the digestive tract: decreased appetite, nausea, vomiting, increased activity of "liver" enzymes.

    From the side of the cardiovascular system: lowering blood pressure (BP).

    From the central nervous system (CNS): headache, weakness, dizziness, confusion, hallucinations, agitation or drowsiness, fever, tremors, convulsions, mental disorders (including delirium), coma.These reactions are most likely in patients receiving high doses of the drug intravenously, as well as in patients with renal insufficiency and AIDS, and are usually reversible.

    From the genitourinary system: peripheral edema, hematuria, an increase in the concentration of urea and creatinine in the blood (however, with a properly selected dose and adequate intake of fluid, no increase is noted), acute renal failure.

    On the part of the hematopoiesis system: anemia, leukopenia, leukocytosis, neutropenia or neutrophilia, thrombocytopenia or thrombocytosis, hemolysis, DIC syndrome, hemolysis. Allergic reactions: skin allergic reactions (itching, rashes, Lyell's syndrome, urticaria, multiforme exudative erythema, including Stevens-Johnson syndrome), anaphylactic reactions.

    From the sense organs: impaired vision.

    Local reactions: phlebitis or inflammation at the site of administration.

    Other: lymphadenopathy.

    Overdose:

    Symptoms: increased urea nitrogen, hypercreatininaemia, impaired renal function, lethargy, convulsions, coma.

    Treatment: maintenance of vital functions, hemodialysis (peritoneal dialysis is less effective).

    Interaction:

    When mixing solutions, the alkaline reaction of acyclovir for intravenous administration (pH 11) should be taken into account.

    An increase in the effect is noted with simultaneous appointment immunostimulants. Probenecid with simultaneous use reduces the tubular secretion of acyclovir and thereby increases the concentration in the blood plasma and the half-life of acyclovir. In the appointment of acyclovir with nephrotoxic drugs the risk of nephrotoxic action increases (especially in patients with impaired renal function). With simultaneous appointment mycophenolate mofetil and acyclovir, plasma concentrations of both drugs increase.

    Acyclovir is incompatible with biological or colloidal solutions, with hydroxybenzoic ethers (parabens) and can be precipitated (pharmaceutical incompatibility).

    Special instructions:

    It should be borne in mind that with the use of acyclovir, the development of acute renal insufficiency is possible due to the formation of a precipitate of acyclovir crystals, which is particularly likely with rapid intravenous administration, simultaneous use of nephrotoxic drugs, in patients with impaired renal function and with dehydration.

    When using acyclovir, it is necessary to control the concentration of urea and creatinine in the blood plasma.

    Long-term treatment with acyclovir patients with reduced immunity can lead to the emergence of strains of viruses that are insensitive to its action.

    Treatment of elderly patients should be carried out with a sufficient increase in water load and under the supervision of a doctor, since this half-life of acyclovir increases in this category of patients.

    In patients receiving the drug in large doses (for example, in herpetic encephalitis), special attention should be given to sufficient fluid intake in the patient's body.

    Acyclovir does not prevent sexual transmission of herpes, therefore during the treatment it is necessary to refrain from sexual intercourse, even in the absence of clinical manifestations.

    The prepared solution can be used for 12 hours from the time of preparation and storage at room temperature (15 to 25 ° C). Unused solutions of the drug should not be stored in the refrigerator for a long time.

    Dissolved acyclovir for infusions should not be taken orally and avoid contact with the eyes.

    Effect on the ability to drive transp. cf. and fur:
    Form release / dosage:

    Lyophilizate for solution for infusion, 250 mg.

    Packaging:The bottle is made of clear, colorless glass, sealed with a rubber stopper, an aluminum cap and a plastic protective cap. 5 bottles with instructions for use packed in a pack of cardboard.
    Storage conditions:

    Store at a temperature not exceeding 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    5 years.

    Do not use the drug after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:П N014287 / 03
    Date of registration:28.02.2008 / 04.12.2013
    Expiration Date:Unlimited
    The owner of the registration certificate:KRKA, dd, Novo mesto, AOKRKA, dd, Novo mesto, AO
    Manufacturer: & nbsp
    KRKA, d.d. Slovenia
    Representation: & nbspKRKA, dd, Novo mesto, AOKRKA, dd, Novo mesto, AO
    Information update date: & nbsp20.02.2017
    Illustrated instructions
      Instructions
      Up